Roche Sees Oncology Access Programs Key To Growth
This article was originally published in PharmAsia News
Against a backdrop of increasing payer scrutiny over the high price tags of new cancer treatments, Roche is looking at two main strategies to ensure access to its therapies in the sector, covering both developed countries and emerging markets.
You may also be interested in...
A new report on China’s pharma innovation ecosystem paints a grim picture of negative market returns for many novel drugs despite shortened review timelines and government calls to encourage innovation.
Regulatory pressure to fully approve the first COVID-19 vaccine in China is mounting as top officials tour an inspection agency and two leading manufacturers.
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.